AUTHOR INDEX
VOLUME 17, 2000

Abulafia, Ovadia, 207
Adra, Abdallah, 249
Adzick, N. Scott, 277
Ahmed, Gasudraz, 121
Alaghehbandan, Reza, 233
Alexander, Sophie, 137
Al-Jarallah, Yousef, 121
Al-Hathal, Muneef, 121
Al-Tawil, Khalil, 121
Andersen, Chad, 219
André, Patrick, 423
Andres, Robert L., 63
Andrews, William W., 357
Arakawa, Yasuyuki, 243
Arbel, Eliana, 159
Arii, Yoshitaro, 53
Armson, B. Anthony, 101
Atherton, Harry D., 257
Atici, Aytuğ, 107
Audibert, François, 423

Ballin, Ami, 159
Bar, Jacob, 237
Barhan, Sheela, 265
Beiner, Mario E., 187
Belik, Jaques, 329
Ben-Shachar, Shay, 163
Bhargava, Ravi, 405
Birnbacher, R., 309
Bishop, Karen, 315
Bofill, James A., 265
Bovicelli, Luciano, 319
Brand, R., 377
Buekens, Pierre, 137

Campbell, Neil, 121
Caramelli, Elisabetta, 319
Cardi, Ettore, 147
Carinci, Paolo, 319
Caritis, Steve N., 41
Carlo, Waldemar A., 1
Cats, Bernard P., 291
Cavaliere, Marisa, 147
Celli, Mauro, 147
Chou, Yi-Hong, 411
Conway, Maureen E., 193
Corrado, Giovanni, 147
Crane, Joan M.G., 101
Creatsas, George, 325
Cunningham-Rundles, Susana, 393

Dande, Dipika, 385
Daneman, Alan, 151
Das, Anita, 41
Dawson, Earl B., 193
Day, Mary-Clare, 63
de Winter, J.P., 377
Degani, Shimon, 127
Dehan, Michel, 423
Demarini, Sergio, 47
Demianczuk, Nestor, 137
D'Eufemia, Patrizia, 147
Dodds, Linda, 101
Dollberg, Shaul, 47, 163, 257
Dombrowski, Mitchell P., 41
Donders, A. Rogier T., 291
Donovan, Edward F., 47
Dulitzky, Mordechai, 187

Eliakim, Rami, 207
Emery, Derek J., 405
Evans, Douglas R., 193
Ezenagu, Leonard C., 265
Ezimokhai, Mutairu, 441

Farina, Antonio, 319
Farmaki, Evangelia, 35
Fenton, Tanis R., 329
Fernandez, Aracelis D., 429
Fuchs, Sonia, 303
Fuller, Leta, 285
Furukawa, Seishi, 371

Gaitini, Luis, 127
Gamsu, Harold R., 73
Giannaki, Galini, 325
Giardini, Omero, 147
Goldberg, Michael, 159
Goldenberg, Robert L., 41, 357
Gonen, Ron, 127
Grisaru, Dan, 303
Guibert, Michèle, 423

Hartmann, Katherine E., 83
Har-Toov, Joseph, 303
Hauth, John C., 357
Hayakawa, Satoshi, 243
Hellmann, Jonathan, 151
Hendson, Leonora, 405
Hoath, Steven B., 47, 257
Hod, Moshe, 237

Horsan, Hayedeh, 233
Hsieh, Wu-Shiun, 411
Huang, Yhu-Chering, 411
Hudak, Mark L., 201

Iams, Jay D., 41
Ikegami, Machiko, 335
Ikenoue, Tsuyomu, 371
Ingardia, Charles J., 183
Inoue, Masaki, 437
Isler, Christy M., 229

Jackson, Tracy P., 83

Kadiltsoglou, Isaac, 35
Kadowaki, Sachiko, 271
Kai, Motoaki, 371
Kajiya, Shoko, 371
Kalhan, Satish, 11
Kallapur, Suhas, 335
Kamitomo, Masato, 371
Katsaveli, Argyro, 35
Katz, Allan R., 299
Kawai, Michiyasu, 53
Karasaki-Suzuki, Miki, 243
Kazzi, S. Nadya J., 131
Kent, Alison, 253
Khalil, Ali, 249
Khan, Nadeem A., 131
Kim, Eugene S., 345
Klinger, Gil, 151
Kohelet, David, 159
Korobochka, Roman, 127
Korones, Sheldon B., 69
Kremenopoulos, George, 35
Kuhle, S., 309
Kuint, Jacob, 187
Kuo, Chii-Yuh, 411
Kupferminc, Michael J., 303
Kurtaran, A., 309
Kyriakides, George, 35

La, Bao-Quoc Core, 315
Lacaze-Masmonteil, Thierry, 423
Larmon, J. Elaine, 229
Larrabee, Kelly, 63
Lemke, Robert P., 405
Lencki, Shaun G., 265
Lerer, Trudy, 183
Lessing, Joseph B., 303

Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. +1(212) 584-4662. 0735-1631,p;2000,17,08,447,448,ftx,en;ajp00012b.

Li, Hongbo, 201
Lien, Rey-In, 411
Lin, Tzou-Yien, 411
Liston, Robert, 101
Lubetzky, Ronit, 163

Maayan-Metsger, Ayala, 237
Magann, Everett F., 417
Malamitsi-Puchner, Ariadne, 325
Manzar, Shabih, 367
Martin Jr., James N., 417
Marx, M., 309
Mashiach, Shlomo, 187
Mastrobattista, Joan M., 299, 315
McGanity, William J., 193
McHugh-Strong, Colette M., 27
McNeeley, David F., 429
McNellis, Donald, 41
Mehdizadeh, Aboulfazl, 233
Meis, Paul J., 41
Menard, M. Kathryn, 41
Menke, James A., 285
Mercer, Brian M., 41
Merth, I.T., 377
Miles, Annette M., 385
Miller, Jonna C., 299
Mimouni, Francis B., 163
Miodovnik, Menachem, 41
Moawad, Atef H., 41
Monga, Manju, 385
Monif, Gilles R.G., 19
Monteiro, Carmela, 201
Morano, Danila, 319
Müller, Peter, 23

Nagle, Claire W., 225
Nakajima, Noriko, 243
Nakamura, Tomohiko, 271
Nesin, Mirjana, 391, 393
Newton, Edward R., 315
Niv, Jakob, 303
Nogee, Lawrence M., 219
Nowaczyk, Malgorzata J.M., 219

Ogundipe, Enitan M., 73
Ohler, Kirsten H., 285
Ohno, Yasumasa, 53
Olley, Peter M., 405
Olvera-López, Antonio, 89
Orvieto, Raoul, 237

Paes, Bosco, 219, 253
Pastore, Lisa M., 83
Pelliccia, Andrea, 147
Perlmutter, Deborah F., 225
Perszyk, Anthony A., 201
Peter-Wohl, Sigal, 11
Phillipos, Ernest Z., 405
Phocas, Iphigenia, 325
Pollak, A., 309
Porcelli, Mariassunta, 147
Premachandra, Bangalore R., 201
Protonotariou, Efthimia, 325
Pschirrer, E.R., 385

Quanjer, Ph.H., 377

Rafael, Zion Ben, 237
Ramsay, Jennifer A., 219
Rimon, Ayelet, 257
Rinehart, Brian K., 229
Rizk, Diaa, 441
Rizos, Dimitrios, 325
Rizzo, Nicola, 319
Roberts, James M., 41
Roberts, William E., 229
Roilides, Emmanuel, 35
Royce, Rachel A., 83
Ruelas-Orozco, Guillermo, 95

Salim, Mubadda A., 69
Salti, Ibrahim, 249
Salzer-Muhar, U., 309
Sameshima, Hiroshi, 371
Sanders, Marilyn R., 27
Santarsiero, Giuseppe, 319
Sarandakou, Angeliki, 325
Sasano, Takuya, 271
Satar, Mehmet, 107
Satoh, Kazuo, 243
Savitz, David A., 83
Schalij-Delfos, Nicoline E., 291
Schiff, Eyal, 187
Seed, Paul, 73
Seoud, Muhieddine, 249
Shah, Jay, 219
Shalev, Yosef, 237
Sharma, Renu, 201
Sherer, David M., 207
Shibata, Yoshihisa, 53
Simchen, Michal J., 187
Sirota, Lea, 237
Skaff, Rana, 249
Steinfeld, Joy D., 183
Stolar, Charles J., 345
Strauss-Liviathan, Nurit, 187
Sutula, Katherine, 183

Talati, Ajay J., 69
Tamura, Masanori, 271
Taylor, Christopher W., 229
Termote, Jacqueline, 291
Terrone, Dom A., 229
Thébaud, Bernard, 423
Thibeault, Donald W., 167
Thomas, Letha, 441
Thome, Ulrich H., 1
Thorp Jr., John M., 83
Thurnau, Gary R., 41
Tough, Suzanne C., 329
Türkmen, Münevver, 107

Uchide, Kiyoshi, 437
Ueno, Hiroiku, 437
Usta, Ihab, 249

Van den Hof, Michiel C., 101
Vannucci, Robert C., 113
Vargas-Origel, Arturo, 89, 95
Vela-Huerta, Ma Martha, 89
Venzon, David, 35
Vitarelli, Marisa, 319
Vogtmann, Christoph, 23

Waller, D. Kim, 385
Walsh, Danielle S., 277
Wax, Joseph R., 183
Wert, Susan E., 219
Wolfe, Charles D.A., 73
Wollast, Elisabeth, 137

Xiong, Xu, 137

Yamamoto, Tatsuo, 243
Yang, Peng-Hong, 411
Yoshinaga, Haruki, 243
Yu, Victor Y.H., 57

SUBJECT INDEX
VOLUME 17, 2000

Abnormal vascular coiling of umbilical cord, maternal risk factors for, 441–445
Achalasia, esophageal, in pregnancy, 53–55
Acidemia, fetal, association of recent cocaine use with, 63–67
Acidosis, transient renal tubular, in pregnancy, 249–252
Advanced practice nurse, evolution of nurse practitioner role in neonatal intensive care unit and, 225–228
AFI, *see* Amniotic fluid index
African-Americans, socioeconomic status as risk factor for bacterial vaginosis in black or in white women, preterm prediction study and, 41–45
Age, gestational, extracorporeal membrane oxygenation in newborn and, 345–346
AIDS, pediatric, management of infant born to mother infected with human immunodeficiency type 1, 429–436
Albumin, assessment of therapy for arterial hypotension in critically ill preterm infants and, 95–99
Amino acids, antioxidant defenses of preterm infant and, 174–175
Aminoglycosides, higher dose extended interval, use of, in neonatal intensive care unit, 285–290
Amniotic fluid index (AFI), cesarean section rate, and labor length in inducted pregnancies beyond 41 weeks' gestation with unfavorable cervix, correlation among, 319–324
Analgesia
  epidural, association between intrapartum fever and, 127–130
  fentanyl–induced muscle rigidity in intensive care of neonates and, 23–26
Anemia during pregnancy, birth outcome and, 137–146
Anomalies, structural and chromosomal, association of single umbilical artery with increased incidence of, 229–232
Antenatal detection of small-for-gestational–age babies, influence of, on their two–year outcomes, 73–81
Antibiotic therapy, effect of, in preterm premature rupture of membranes on neonatal mortality and morbidity, 237–241
Antiemetics, hyperemesis gravidarum and, 213
Antimicrobial therapy, congenital chylothorax and, 123
Antioxidant defenses, precarious, of preterm infants, 167–181
Antioxidant enzymes, 167–168
Antiretroviral therapy, human immunodeficiency syndrome and, 433
Aortic thrombosis, severe, in neonates, treatment of, with low-molecular-weight heparin, 151–158
Arterial hypotension, assessment of therapy for, in critically ill preterm infants, 95–99
Arteriovenous malformation, intracranial, of vein of Galen, persistent pulmonary hypertension of newborn presenting as primary manifestation of, 405–410
Asphyxia, hypoxic-ischemic encephalopathy and, 113–120
Asymmetrical septal hypertrophy in newborn infants of diabetic mothers, 89–94
Autonomic nervous dysfunction, hyperemesis gravidarum and, 210–211
Autopsy, perinatal lethal form of Gaucher's disease and, 203
Autosomal recessive, recurrent familial neonatal deaths, hereditary surfactant protein B deficiency and, 219–224
Axillary temperature, continuous measurement of core body temperature in preterm infants and, 257–264

Bacterial vaginosis (BV)
  and cervical dilation and effacement at 24–29 weeks' gestation, 83–88
  Gram-stain diagnosis of, after rupture of membranes, 315–318
  socioeconomic status as risk factor for, in black or in white women, preterm prediction study and, 41–45
Bilirubin, antioxidant defenses of preterm infant and, 171
Bioavailability, vitamin B12 and folate, from two prenatal multivitamin/multimineral supplements, 193–199
Biochemistry
  hypoxic-ischemic encephalopathy and, 117
  surfactants and, 335–336
Bioethics, newborn intensive care deaths in tertiary setting and, 27–33
Birth, preterm, *see* Preterm birth
Birth outcome, anemia during pregnancy and, 137–146
Birth weight
  extracorporeal membrane oxygenation in newborn and, 346
  low, *see* Low birth weight
  serum leptin concentrations during perinatal period and, 325–328
Black women, socioeconomic status as risk factor for bacterial vaginosis in, preterm prediction study and, 41–45
Bleeding, extracorporeal membrane oxygenation in newborn and, 346
Blood gases, umbilical, association of recent cocaine use with fetal acidemia or other manifestations of intrapartum fetal distress and, 63–67
Blood volume, neonatal hematocrit and, 163–165
Body temperature, core, continuous measurement of, in preterm infants, 257–264
BPD, *see* Bronchopulmonary dysplasia
Brain, hypoxic-ischemic encephalopathy and, 113–120
Breast feeding
  breast milk supplementation for preterm infants and, 329–333
  human immunodeficiency syndrome and, 429–436
  hypoglycemia and, 11–18
  for preterm infants, parental preferences and postdischarge lactation duration, 329–333
  Sandifer's syndrome in, 147–150
Breast milk supplementation for preterm infants, parental preferences and postdischarge lactation duration, 329–333
Breech delivery, successful, labor and delivery following external cephalic version, 183–186
Bronchopulmonary dysplasia (BPD)
  congenital chylothorax and, 121–126

Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. +1(212) 584-4662. 0735-1631,p;2000,17,08,449,458,ftx,en;ajp00013c.

Bronchopulmonary dysplasia (BPD) *(continued)*
high-frequency ventilation in neonates and, 1–9
relationship of postnatal glucocorticoids with retinopathy of prematurity and, 291–298
BV, *see* Bacterial vaginosis

Candidemia, neonatal, fluconazole therapy in, 411–415
Care
perinatal, *see* Perinatal care
prenatal, *see* Prenatal care
Caucasians, socioeconomic status as risk factor for bacterial vaginosis in black or in white women, preterm prediction study and, 41–45
Central nervous system involvement without dermatological features, congenital varicella syndrome and, 253–256
Central pontine myelinolysis, hyperemesis gravidarum and, 212
Cephalic version, external, successful, labor and delivery following, 183–186
Cerebral arteries, vasospasm of, hyperemesis gravidarum and, 212–213
Ceruloplasmin, antioxidant defenses of preterm infant and, 171–172
Cervical dilation and effacement, bacterial vaginosis and, at 24–29 weeks' gestation, 83–88
Cervical incompetence, modifications to modified Shirodkar operation and, 437–439
Cervix, unfavorable, correlation among amniotic fluid index, cesarean section rate, and labor length in inducted pregnancies beyond 41 weeks' gestation with, 319–324
Cesarean section (CS)
amniotic fluid index, and labor length in inducted pregnancies beyond 41 weeks' gestation with unfavorable cervix, correlation among, 319–324
elective repeat, instrumental delivery of fetal head at time of, 265–269
neonatal hematocrit and, 163–165
successful, labor and delivery following external cephalic version, 183–186
Chemotaxis, neutrophil, and random migration in preterm and term infants with sepsis, 107–112
Chorioamnionitis, maternal-fetal staphylococcal infections and, 423–427
Chromosomal anomalies, association of single umbilical artery with increased incidence of, 229–232
Chronic lung disease (CLD)
high-frequency ventilation in neonates and, 1–9
variations in neutrophil count in preterm infants with respiratory distress syndrome who subsequently developed, 159–162
Chylothorax, congenital, 121–126
CLD, *see* Chronic lung disease
Clinical versus ultrasound estimation of fetal weight, comparison of, 233–236
Closed system helium dilution, surfactants and, 380
Cocaine, recent use of, association of, with fetal acidemia or other manifestations of intrapartum distress, 63–67
Cohort study, influence of antenatal detection of small-for-gestational-age babies on their two-year outcomes, 73–81
Coiling, abnormal vascular, of umbilical cord, maternal risk factors for, 441–445
Compliance, static, and functional residual capacity, during first year in preterm infants treated with surfactant, 377–384
Congenital chylothorax, 121–126
Congenital diaphragmatic hernia, extracorporeal membrane oxygenation in infants with, 351
Congenital infection, maternal-fetal staphylococcal infections and, 423–427
Congenital varicella syndrome, central nervous system involvement without dermatological features, 253–256
Continous indomethacin, low-dose, in early days of age in reduction of incidence of symptomatic patent ductus arteriosus without adverse effects, 271–275
Continuous measurement of core body temperature in preterm infants, 257–264
Contractile agents, uterine, risk factors for symptomatic uterine rupture during trial of labor, 385–389
Cord, umbilical, *see* Umbilical cord
Core body temperature, continuous measurement of, in preterm infants, 257–264
Corticosteroids, critical care of HELLP syndrome with, 417–422
Costs of screening growth-retarded infants for TORCH infections, 131–135
Cox algorithm, correlation among amniotic fluid index, cesarean section rate, and labor length in inducted pregnancies beyond 41 weeks' gestation with unfavorable cervix and, 319–324
Critically ill preterm infants, assessment of therapy for arterial hypotension in, 95–99
CS, *see* Cesarean section
Cytokines and neonates, 393–404

Deaths
intrauterine fetal, esophageal achalasia in pregnancy and, 53–55
newborn intensive care, in tertiary setting, 27–33
recurrent familial neonatal, hereditary surfactant protein B deficiency and, 219–224
Delivery
breech, successful, labor and delivery following external cephalic version, 183–186
cesarean, *see* Cesarean section
instrumental, of fetal head, at time of elective repeat cesarean, 265–269
labor and, following successful external cephalic version, 183–186
twin, outcome of, according to first twin presentation and method of delivery, 303–307
vaginal, neonatal hematocrit and, 163–165
Dermatological features, central nervous system involvement without, congenital varicella syndrome and, 253–256
Detection, antenatal, of small-for-gestational-age babies, influence of, on their two-year outcomes, 73–81
Developmental immunology, cytokines and neonates and, 393–404
Developmental outcome of extremely preterm infants, 57–61
Diabetes, gestational, *see* Gestational diabetes
Diabetic mothers, asymmetrical septal hypertrophy in newborn infants of, 89–94
Diaphragmatic hernia, congenital, extracorporeal membrane oxygenation in infants with, 351
Dilation, cervical, and effacement, bacterial vaginosis and, at 24–29 weeks' gestation, 83–88
Distress, fetal, intrapartum, association of recent cocaine use with, 63–67
Do not resuscitate, newborn intensive care deaths in tertiary setting and, 27–33

Dobutamine, assessment of therapy for arterial hypotension in critically ill preterm infants and, 95–99
Dopamine, assessment of therapy for arterial hypotension in critically ill preterm infants and, 95–99
Dosing guidelines, use of higher dose extended interval aminoglycosides in neonatal intensive care unit, 285–290
Ductus arteriosus
  patent, symptomatic, low-dose continuous indomethacin in early days of age in reduction of incidence of, without adverse effects, 271–275
  persistent pulmonary hypertension after maternal naproxen ingestion in term newborns, 69–71
Dysplasia, bronchopulmonary, *see* Bronchopulmonary dysplasia

Early glycemic control in reduction of large-for-gestational-age infants, gestational diabetes pregnancies and, 371–376
ECMO, *see* Extracorporeal membrane oxygenation
EEG, *see* Electroencephalography
Effacement, cervical dilation and, bacterial vaginosis and, at 24–29 weeks' gestation, 83–88
Elective repeat cesarean, instrumental delivery of fetal head at time of, 265–269
Electroencephalography (EEG), hypoxic-ischemic encephalopathy and, 116–117
Electrolytes, hyperemesis gravidarum and, 213
Embolization, endovascular, persistent pulmonary hypertension of newborn presenting as primary manifestation of intracranial arteriovenous malformation of vein of Galen and, 405–410
Embryopathy, congenital varicella syndrome and, 253–256
Emulsion, fat, antioxidant defenses of preterm infant and, 173–174
Encephalopathy
  hypoxic-ischemic, 113–120
  Wernicke's, hyperemesis gravidarum and, 212
Endovascular embolization, persistent pulmonary hypertension of newborn presenting as primary manifestation of intracranial arteriovenous malformation of vein of Galen and, 405–410
Enteral nutrition, hyperemesis gravidarum and, 214–215
Enterobacteriaceae, perinatal septicemia due to, maternal risk factors for, 19–22
Enzymes, antioxidant, 167–168
Epidemiology, bacterial vaginosis and cervical dilation and effacement at 24–29 weeks' gestation and, 83–88
Epidural analgesia, association between intrapartum fever and, 127–130
Esophageal achalasia in pregnancy, 53–55
Esophageal rupture, hyperemesis gravidarum and, 213
Extended interval aminoglycosides, higher dose, use of, in neonatal intensive care unit, 285–290
External cephalic version, successful, labor and delivery following, 183–186
Extracorporeal membrane oxygenation (ECMO)
  in newborn, 345–356
  veno-venous versus veno-arterial, 347
Extremely preterm infants, developmental outcome of, 57–61

Familial neonatal deaths, recurrent, hereditary surfactant protein B deficiency and, 219–224
Fat emulsion, antioxidant defenses of preterm infant and, 173–174
Fat soluble compounds, antioxidant defenses of preterm infant and, 170
Fentanyl-induced muscle rigidity, intensive care of neonates and, 23–26
Fentanyl-induced thoracic rigidity, intensive care of neonates and, 23–26
Fetal acidemia, association of recent cocaine use with, 63–67
Fetal death, intrauterine, esophageal achalasia in pregnancy and, 53–55
Fetal distress, intrapartum, association of recent cocaine use with, 63–67
Fetal growth restriction, anemia during pregnancy and, 137–146
Fetal head, instrumental delivery of, at time of elective repeat cesarean, 265–269
Fetal hypoxia, maternal sickle cell trait and, 367–370
Fetal surgical intervention, 277–283
Fetal weight, comparison of clinical versus ultrasound estimation of, 233–236
Fetus, hypoxic-ischemic encephalopathy and, 113–120
Fever, intrapartum, association between epidural analgesia and, 127–130
Fluconazole therapy in neonatal candidemia, 411–415
Fluid electrolytes, hyperemesis gravidarum and, 213
Folate and vitamin B12 bioavailability from two prenatal multivitamin/multimineral supplements, 193–199
Forceps, instrumental delivery of fetal head at time of elective repeat cesarean and, 265–269
Functional residual capacity and static compliance during first year in preterm infants treated with surfactant, 377–384

Galen, vein of, persistent pulmonary hypertension of newborn presenting as primary manifestation of intracranial arteriovenous malformation of, 405–410
Gases, blood, umbilical, association of recent cocaine use with fetal acidemia or other manifestations of intrapartum fetal distress and, 63–67
Gastritis, latent, frequent presence of Helicobacter pylori genome in saliva of patients with hyperemesis gravidarum, 243–247
Gastroesophageal reflux disease, Sandifer's syndrome in breast-fed infant and, 147–150
Gaucher's disease, perinatal lethal form of, presenting with hemosiderosis, 201–206
Genital tract infection, infection and preterm birth and, 357–365
Genome, Helicobacter pylori, frequent presence of, in saliva of patients with hyperemesis gravidarum, 243–247
Gestation
  24–29 weeks', bacterial vaginosis and cervical dilation and effacement at, 83–88
  41 weeks', correlation among amniotic fluid index, cesarean section rate, and labor length in inducted pregnancies with unfavorable cervix, 319–324
Gestational age, extracorporeal membrane oxygenation in newborn and, 345–346
Gestational diabetes
  early glycemic control in reduction of large-for-gestational-age infants in, 371–376
  maternal risk factors for abnormal vascular coiling of umbilical cord, 441–445
Ginger, hyperemesis gravidarum and, 214
Glucocorticoids, postnatal, relationship of retinopathy of prematurity with, 291–298

Glucose, hypoglycemia in neonates and, 11–18
Glutathione, antioxidant defenses of preterm infant and, 172–173
Glycemic control, early, in reduction of large-for-gestational-age infants, gestational diabetes pregnancies and, 371–376
Gram-stain diagnosis of bacterial vaginosis after rupture of membranes, 315–318
Growth, fetal, restriction of, anemia during pregnancy and, 137–146
Growth restriction, association of single umbilical artery with increased incidence of, 229–232
Growth retardation, intrauterine, yield and costs of screening growth-retarded infants for TORCH infections and, 131–135
Growth-restricted versus approximately grown preterm infants, neonatal outcome in, 187–192
Growth-retarded infants, screening, for TORCH infections, yield and costs of, 131–135

Head, fetal, instrumental delivery of, at time of elective repeat cesarean, 265–269
Helicobacter pylori, hyperemesis gravidarum and, 210
Helicobacter pylori genome, frequent presence of, in saliva of patients with hyperemesis gravidarum, 243–247
Helium dilution, closed system, surfactants and, 380
HELLP syndrome, critical care of, with corticosteroids, 417–422
Hematocrit, neonatal, mode of delivery and, 163–165
Hematologic problems of neonate, 391–392
Hemolysis, elevated liver enzymes, and low platelets, *see* HELLP syndrome
Hemorrhage
  intracranial, *see* Intracranial hemorrhage
  intraventricular, high-frequency ventilation in neonates and, 1–9
Hemosiderosis, perinatal lethal form of Gaucher's disease presenting with, 201–206
Heparin, low-molecular-weight, treatment of severe aortic thrombosis in neonates with, 151–158
Hepatic abnormalities, hyperemesis gravidarum and, 210
Hereditary surfactant protein B deficiency, recurrent familial neonatal deaths and, 219–224
Hernia, congenital diaphragmatic, extracorporeal membrane oxygenation in infants with, 351
Higher dose extended interval aminoglycosides, use of, in neonatal intensive care unit, 285–290
High-frequency ventilation in neonates, 1–9
HIV-1, *see* Human immunodeficiency virus type 1
Homeothermy, maturation of thermal capabilities in preterm infants and, 47–51
Hormones, hyperemesis gravidarum and, 208
Human immunodeficiency virus type 1 (HIV-1), management of infant born to mother infected with, 429–436
Human milk, Sandifer's syndrome in breast-fed infant and, 147–150, *see also* Breast feeding
Hyaline membrane disease, recurrent familial neonatal deaths, hereditary surfactant protein B deficiency and, 219–224
Hydrocortisone, relationship of postnatal glucocorticoids with retinopathy of prematurity and, 291–298
Hydrops fetalis
  congenital chylothorax and, 121–126
  fetal surgical intervention and, 277–283
  nonimmune, perinatal lethal form of Gaucher's disease presenting with hemosiderosis and, 201–206
Hyperemesis gravidarum, 207–218
  frequent presence of Helicobacter pylori genome in saliva of patients with, 243–247
Hyperferritinemia, perinatal lethal form of Gaucher's disease presenting with hemosiderosis and, 201–206
Hypertension, persistent pulmonary
  after maternal naproxen ingestion in term newborns, 69–71
  of newborn presenting as primary manifestation of intracranial arteriovenous malformation of vein of Galen, 405–410
Hypertrophy, asymmetrical septal, in newborn infants of diabetic mothers, 89–94
Hypoglycemia in neonates, 11–18
Hypotension, arterial, assessment of therapy for, in critically ill preterm infants, 95–99
Hypoxia, fetal, maternal sickle cell trait and, 367–370
Hypoxic-ischemic encephalopathy, 113–120

Ichthyosis, perinatal lethal form of Gaucher's disease presenting with hemosiderosis and, 201–206
Immunology, developmental, cytokines and neonates and, 393–404
Incompetence, cervical, modifications to modified Shirodkar operation and, 437–439
Incubator, continuous measurement of core body temperature in preterm infants and, 257–264
Indomethacin, low-dose continuous, in early days of age in reduction of incidence of symptomatic patent ductus arteriosus without adverse effects, 271–275
Inducted pregnancies, correlation among amniotic fluid index, cesarean section rate, and labor length in, beyond 41 weeks' gestation with unfavorable cervix, 319–324
Infants
  born to mother infected with human immunodeficiency virus type 1 (HIV-1), 429–436
  breast-fed, *see* Breast feeding
  of diabetic mothers, asymmetrical septal hypertrophy in, 89–94
  growth-retarded, screening, for TORCH infections, yield and costs of, 131–135
  large-for-gestational-age, early glycemic control in reduction of, in gestational diabetes pregnancies, 371
  macrosomic, asymmetrical septal hypertrophy in newborn infants of diabetic mothers, 89–94
  newborn, *see* Newborn infants
  preterm, *see* Prematurity; Preterm infants
  serum leptin concentrations during perinatal period and, 325–328
  small-for-gestational-age, *see* Small-for-gestational-age infants
  term, *see* Term newborns
Infarction, myocardial, intrauterine, survival after, noninvasive assessment of myocardial perfusion with 99MTc-Sestamibi scintigraphy and, 309–313
Infection
  congenital, maternal-fetal staphylococcal infections and, 423–427
  genital tract, infection and preterm birth and, 357–365
  human immunodeficiency type 1, management of infant born to mother infected with, 429–436
  intrauterine, yield and costs of screening growth-retarded infants for TORCH infections and, 131–135
  maternal-fetal staphylococcal, 423–427
  neonatal, 391
  and preterm birth, 357–365
  TORCH, yield and costs of screening growth-retarded infants for, 131–135

Instrumental delivery of fetal head at time of elective repeat cesarean, 265–269
Intensive care of neonates, *see* Neonates, intensive care of
Intensive care unit, neonatal, *see* Neonatal intensive care unit
Intracranial arteriovenous malformation of vein of Galen, persistent pulmonary hypertension of newborn presenting as primary manifestation of, 405–410
Intracranial hemorrhage
  extracorporeal membrane oxygenation in newborn and, 346
  high-frequency ventilation in neonates and, 1–9
Intrapartum fetal distress, association of recent cocaine use with, 63–67
Intrapartum fever, association between epidural analgesia and, 127–130
Intrauterine fetal death, esophageal achalasia in pregnancy and, 53–55
Intrauterine growth retardation, yield and costs of screening growth-retarded infants for TORCH infections and, 131–135
Intrauterine infection, yield and costs of screening growth-retarded infants for TORCH infections and, 131–135
Intrauterine myocardial infarction, survival after, noninvasive assessment of myocardial perfusion with 99MTc-Sestamibi scintigraphy and, 309–313
Intraventricular hemorrhage, high-frequency ventilation in neonates and, 1–9
Iron, antioxidant defenses of preterm infant and, 171–172
Ischemia, hypoxic-ischemic encephalopathy and, 113–120
IUGR, growth-restricted versus approximately grown preterm infants, neonatal outcome in, 187–192

Kaplan-Meier algorithm, correlation among amniotic fluid index, cesarean section rate, and labor length in inducted pregnancies beyond 41 weeks' gestation with unfavorable cervix and, 319–324
Klebsiella pneumoniae, multiresistant, in neonatal unit, septicemia due to, 35–39

Labor
  and delivery following successful external cephalic version, 183–186
  length of, amniotic fluid index, and cesarean section in inducted pregnancies beyond 41 weeks' gestation with unfavorable cervix, correlation among, 319–324
  neonatal hematocrit and, 163–165
  premature, cytokines and, 393–404
  trial of, risk factors for symptomatic uterine rupture during, 385–389
Lactation, postdischarge duration of, breast milk supplementation for preterm infants and, 329–333
Large-for-gestational-age (LGA) infants, early glycemic control in reduction of, gestational diabetes pregnancies and, 371–376
Latent gastritis, frequent presence of Helicobacter pylori genome in saliva of patients with hyperemesis gravidarum, 243–247
Leptin, serum, concentrations of, during perinatal period, 325–328
Lethal form, perinatal, of Gaucher's disease presenting with hemosiderosis, 201–206
LGA infants, *see* Large-for-gestational-age infants
Lipid metabolism, hyperemesis gravidarum and, 210
Liver transplantation, obstetrical and neonatal outcome in pregnancies after, 299–302
Low birth weight
  anemia during pregnancy and, 137–146
  breast milk supplementation for preterm infants and, 329–333
  infection and preterm birth and, 357–365
  maturation of thermal capabilities in preterm infants and, 47–51
Low-dose continuous indomethacin in early days of age in reduction of incidence of symptomatic patent ductus arteriosus without adverse effects, 271–275
Low-molecular-weight heparin, treatment of severe aortic thrombosis in neonates with, 151–158
Lung disease, chronic, *see* Chronic lung disease
Lung function testing, functional residual capacity and static compliance during first year in preterm infants treated with surfactant and, 377–384

Macrosomic infants, asymmetrical septal hypertrophy in newborn infants of diabetic mothers, 89–94
Maternal complications with placenta previa, 100–105
Maternal naproxen ingestion, persistent pulmonary hypertension after, in term newborns, 69–71
Maternal risk factors
  for abnormal vascular coiling of umbilical cord, 441–445
  for perinatal septicemia due to Enterobacteriaceae, 19–22
Maternal serum, serum leptin concentrations during perinatal period and, 325–328
Maternal sickle cell trait and fetal hypoxia, 367–370
Maternal temperature, association between epidural analgesia and intrapartum fever and, 127–130
Maternal-fetal staphylococcal infections, 423–427
Maturation of thermal capabilities in preterm infants, 47–51
Mechanical ventilation, high-frequency, in neonates, 1–9
Medium chain triglycerides rich formula, congenital chylothorax and, 121–126
Membranes
  preterm premature rupture of, effect of antibiotic therapy in, on neonatal mortality and morbidity, 237–241
  rupture of, Gram-stain diagnosis of bacterial vaginosis after, 315–318
Meta-analysis, anemia during pregnancy and birth outcome and, 137–146
Microophthalmia, congenital varicella syndrome and, 253–256
Migration, random, neutrophil chemotaxis and, in preterm and term infants with sepsis, 107–112
Milk, human, *see* Breast feeding
Mode of delivery, *see* Delivery
Modified Shirodkar operation, modifications to, 437–439
Morbidity, neonatal, effect of antibiotic therapy in preterm premature rupture of membranes on, 237–241
Mortality
  neonatal, effect of antibiotic therapy in preterm premature rupture of membranes on, 237–241
  perinatal, anemia during pregnancy and birth outcome and, 137–146
Mother
  diabetic, asymmetrical septal hypertrophy in newborn infants of, 89–94
  infected with human immunodeficiency virus type 1 (HIV-1), management of infant born to, management of, 429–436
Multimineral supplements, prenatal, vitamin B12 and folate bioavailability from, 193–199

Multiresistant Klebsiella pneumoniae in neonatal unit, septicemia due to, 35–39
Multivitamins
antioxidant defenses of preterm infant and, 174–175
prenatal, vitamin B12 and folate bioavailability from, 193–199
Muscle rigidity, fentanyl-induced, intensive care of neonates and, 23–26
Myocardial infarction, intrauterine, survival after, noninvasive assessment of myocardial perfusion with 99MTc-Sestamibi scintigraphy and, 309–313
Myocardial perfusion, noninvasive assessment of, with 99MTc-Sestamibi scintigraphy, survival after intrauterine myocardial infarction and, 309–313

Naproxen, maternal ingestion of, persistent pulmonary hypertension after, in term newborns, 69–71
Nausea, hyperemesis gravidarum and, 207–218
NEC, cytokines and neonates and, 393–404
Neonatal candidemia, fluconazole therapy in, 411–415
Neonatal deaths, recurrent familial, hereditary surfactant protein B deficiency and, 219–224
Neonatal hematocrit, mode of delivery and, 163–165
Neonatal infections, 391
Neonatal intensive care unit (NICU)
evolution of nurse practitioner role in, 225–228
use of higher dose extended interval aminoglycosides in, 285–290
Neonatal mortality and morbidity, effect of antibiotic therapy in preterm premature rupture of membranes on, 237–241
Neonatal nurse practitioner, evolution of role in neonatal intensive care unit, 225–228
Neonatal outcome
in growth-restricted versus approximately grown preterm infants, 187–192
in pregnancies after liver transplantation, 299–302
Neonatal sepsis
cytokines and, 393–404
growth-restricted versus approximately grown preterm infants, neonatal outcome in, 187–192
Neonatal unit, multiresistant Klebsiella pneumoniae in, septicemia due to, 35–39
Neonates, *see also* Newborn infants
cytokines and, 393–404
early glycemic control in reduction of large-for-gestational-age infants in gestational diabetes pregnancies, 371–376
extracorporeal membrane oxygenation in, 345–356
fluconazole therapy in neonatal candidemia, 411–415
hematologic problems of, 391–392
high-frequency ventilation in, 1–9
hypoglycemia in, 11–18
intensive care of
deaths in tertiary setting and, 27–33
fentanyl-induced muscle rigidity in, 23–26
septicemia due to multiresistant Klebsiella pneumoniae in neonatal unit and, 35–39
severe aortic thrombosis in, treatment of, with low-molecular-weight heparin, 151–158
splenomegaly in, perinatal lethal form of Gaucher's disease presenting with hemosiderosis and, 201–206
survival after intrauterine myocardial infarction and, 309–313
use of higher dose extended interval aminoglycosides in neonatal intensive care unit, 285–290
Neuro-imaging, hypoxic-ischemic encephalopathy and, 116
Neurological assessment, hypoxic–ischemic encephalopathy and, 114–116
Neurology, congenital varicella syndrome and, 253–256
Neutrophil chemotaxis and random migration in preterm and term infants with sepsis, 107–112
Neutrophil count, variations in, in preterm infants with respiratory distress syndrome who subsequently developed chronic lung disease, 159–162
Newborn infants, *see also* Neonates
breast–fed, hypoglycemia and, 11–18
of diabetic mothers, asymmetrical septal hypertrophy in, 89–94
extracorporeal membrane oxygenation in, 345–356
hypoglycemia in, 11–18
maternal–fetal staphylococcal infections and, 423–427
persistent pulmonary hypertension of, presenting as primary manifestation of intracranial arteriovenous malformation of vein of Galen, 405–410
term, *see* Term newborns
NICU, *see* Neonatal intensive care unit
Nitric oxide, antioxidant defenses of preterm infant and, 175
Nonimmune hydrops fetalis, perinatal lethal form of Gaucher's disease presenting with hemosiderosis and, 201–206
Noninvasive assessment of myocardial perfusion with 99MTc–Sestamibi scintigraphy, survival after intrauterine myocardial infarction and, 309–313
Nonsteroidal anti–inflammatory drugs (NSAIDs), persistent pulmonary hypertension after maternal naproxen ingestion in term newborns, 69–71
NRBC count, *see* Nucleated red blood cell count
NSAIDs, *see* Nonsteroidal anti–inflammatory drugs
Nucleated red blood cell (NRBC) count, maternal sickle cell trait and fetal hypoxia and, 367–370
Nurse, advanced practice, evolution of nurse practitioner role in neonatal intensive care unit and, 225–228
Nurse practitioner
evolution of role of, in neonatal intensive care unit, 225–228
neonatal, evolution of role in neonatal intensive care unit, 225–228
Nutrition
breast milk supplementation for preterm infants and, 329–333
congenital chylothorax and, 122
enteral, hyperemesis gravidarum and, 214–215
hyperemesis gravidarum and, 211
parenteral, *see* Parenteral nutrition

Obstetrical outcome in pregnancies after liver transplantation, 299–302
Osmotic demyelination syndrome, hyperemesis gravidarum and, 212
Oxygen radicals, precarious antioxidant defenses of preterm infants and, 167–181

Parental preferences, breast milk supplementation for preterm infants and, 329–333
Parenteral nutrition
antioxidant defenses of preterm infant and, 173–175
hyperemesis gravidarum and, 215
total, congenital chylothorax and, 121–126
Patent ductus arteriosus, symptomatic, low-dose continuous indomethacin in early days of age in reduction of incidence of, without adverse effects, 271–275

PCP, *see* Pneumocystis carinii pneumonia
PCR, frequent presence of Helicobacter pylori genome in saliva of patients with hyperemesis gravidarum, 243–247
Pediatric AIDs, management of infant born to mother infected with human immunodeficiency type 1, 429–436
Pediatric HIV infection, management of infant born to mother infected with human immunodeficiency virus type 1 (HIV–1), 429–436
Perfusion, myocardial, noninvasive assessment of, with 99MTc–Sestamibi scintigraphy, survival after intrauterine myocardial infarction and, 309–313
Perinatal care
  hypoxic–ischemic encephalopathy and, 113–120
  regionalization of, developmental outcome of extremely preterm infants, 57–61
Perinatal lethal form of Gaucher's disease presenting with hemosiderosis, 201–206
Perinatal mortality, anemia during pregnancy and birth outcome and, 137–146
Perinatal period, serum leptin concentrations during, 325–328
Perinatal septicemia due to Enterobacteriaceae, maternal risk factors for, 19–22
Perinatal transmission of HIV, management of infant born to mother infected with human immunodeficiency type 1, 429–436
Pernicious vomiting, hyperemesis gravidarum and, 207–218
Persistent pulmonary hypertension
  after maternal naproxen ingestion in term newborns, 69–71
  of newborn presenting as primary manifestation of intracranial arteriovenous malformation of vein of Galen, 405–410
Placenta, serum leptin concentrations during perinatal period and, 325–328
Placenta previa, maternal complications with, 100–105
Pneumocystis carinii pneumonia (PCP), human immunodeficiency syndrome and, 433
Pneumomediastinum, hyperemesis gravidarum and, 213
Pneumonia, Pneumocystis carinii, human immunodeficiency syndrome and, 433
Polycythemia, mode of delivery and neonatal hematocrit and, 163–165
Postdischarge lactation duration, breast milk supplementation for preterm infants and, 329–333
Postnatal glucocorticoids, relationship of retinopathy of prematurity with, 291–298
Postneonatal outcomes, influence of antenatal detection of small-for-gestational-age babies on their two–year outcomes, 73–81
Post-term pregnancy, correlation among amniotic fluid index, cesarean section rate, and labor length in inducted pregnancies beyond 41 weeks' gestation with unfavorable cervix and, 319–324
P-PROM, *see* Preterm premature rupture of membranes
Practitioner, nurse, *see* Nurse practitioner
Precarious antioxidant defenses of preterm infants, 167–181
Preeclampsia
  maternal risk factors for abnormal vascular coiling of umbilical cord and, 441–445
  severe, critical care of HELLP syndrome with corticosteroids and, 417–422
Pregnancy
  after liver transplantation, obstetrical and neonatal outcome in, 299–302
  anemia during, birth outcome and, 137
  association of recent cocaine use with fetal acidemia or other manifestations of intrapartum fetal distress and, 63–67
  esophageal achalasia in, 53–55
  gestational diabetes, early glycemic control in reduction of large-for-gestational-age infants in, 371–376
  hyperemesis gravidarum and, 207–218
  inducted, correlation among amniotic fluid index, cesarean section rate, and labor length in, beyond 41 weeks' gestation with unfavorable cervix, 319–324
  post–term, correlation among amniotic fluid index, cesarean section rate, and labor length in inducted pregnancies beyond 41 weeks' gestation with unfavorable cervix and, 319–324
  socioeconomic status as risk factor for bacterial vaginosis in black or in white women, preterm prediction study and, 41–45
Premature labor, cytokines and, 393–404
Premature rupture of membranes, preterm, effect of antibiotic therapy in, on neonatal mortality and morbidity, 237–241
Prematurity, *see also* Preterm infants
  developmental outcome of extremely preterm infants, 57–61
  functional residual capacity and static compliance during first year in preterm infants treated with surfactant and, 377–384
  high–frequency ventilation in neonates and, 1–9
  maternal–fetal staphylococcal infections and, 423–427
  retinopathy of, relationship of postnatal glucocorticoids with, 291–298
Prenatal care
  association of recent cocaine use with fetal acidemia or other manifestations of intrapartum fetal distress and, 63–67
  persistent pulmonary hypertension after maternal naproxen ingestion in term newborns, 69–71
Prenatal diagnosis
  fetal surgical intervention and, 277–283
  recurrent familial neonatal deaths, hereditary surfactant protein B deficiency and, 219–224
Prenatal multivitamin/multimineral supplements, vitamin B12 and folate bioavailability from, 193–199
Presentation, outcome of twin deliveries according to first twin presentation and method of delivery, 303–307
Preterm birth
  anemia during pregnancy and birth outcome and, 137–146
  infection and, 357–365
Preterm infants, *see also* Prematurity
  breast milk supplementation for, parental preferences and postdischarge lactation duration, 329–333
  continuous measurement of core body temperature in, 257–264
  critically ill, assessment of therapy for arterial hypotension in, 95–99
  extremely, developmental outcome of, 57–61
  growth–restricted versus approximately grown, neonatal outcome in, 187–192
  hypoglycemia and, 11–18
  maturation of thermal capabilities in, 47–51
  precarious antioxidant defenses of, 167–181
  with respiratory distress syndrome who subsequently developed chronic lung disease,variations in neutrophil count in, 159–162

Preterm infants *(continued)*
with sepsis, neutrophil chemotaxis and random migration in, 107–112
socioeconomic status as risk factor for bacterial vaginosis in black or in white women, 41–45
treated with surfactant, functional residual capacity and static compliance during first year in, 377–384
Preterm premature rupture of membranes (P-PROM), effect of antibiotic therapy in, on neonatal mortality and morbidity, 237–241
Pro-inflammatory cytokines, neonates and, 393–404
Prophylaxis, effect of antibiotic therapy in preterm premature rupture of membranes on neonatal mortality and morbidity, 237–241
Protein B deficiency, hereditary surfactant, recurrent familial neonatal deaths and, 219–224
Psychological factors, hyperemesis gravidarum and, 211
Pulmonary hypertension, persistent
after maternal naproxen ingestion in term newborns, 69–71
of newborn presenting as primary manifestation of intracranial arteriovenous malformation of vein of Galen, 405–410
PVL, cytokines and neonates and, 393–404

Race, socioeconomic status as risk factor for bacterial vaginosis in black or in white women, preterm prediction study and, 41–45
Radiant warmer, continuous measurement of core body temperature in preterm infants and, 257–264
Radicals, oxygen, precarious antioxidant defenses of preterm infants and, 167–181
Random migration, neutrophil chemotaxis and, in preterm and term infants with sepsis, 107–112
RDS, *see* Respiratory distress syndrome
Recessive, autosomal, recurrent familial neonatal deaths, hereditary surfactant protein B deficiency and, 219–224
Recurrent familial neonatal deaths, hereditary surfactant protein B deficiency and, 219–224
Reflux, gastroesophageal, Sandifer's syndrome in breast-fed infant and, 147–150
Regionalization of perinatal care, developmental outcome of extremely preterm infants, 57–61
Removal of Shirodkar tape, modifications to modified Shirodkar operation and, 437–439
Renal tubular acidosis, transient, in pregnancy, 249–252
Repeat cesarean, elective, instrumental delivery of fetal head at time of, 265–269
Residual capacity, functional, and static compliance, during first year in preterm infants treated with surfactant, 377–384
Respiratory distress syndrome (RDS)
high–frequency ventilation in neonates and, 1–9
surfactants and, 335–342
variations in neutrophil count in preterm infants with, who subsequently developed chronic lung disease, 159–162
Respiratory failure, extracorporeal membrane oxygenation in, 345–356
Resuscitation, newborn intensive care deaths in tertiary setting and, 27–33
Retinopathy of prematurity, relationship of postnatal glucocorticoids with, 291–298
Rigidity
muscle, fentanyl–induced, intensive care of neonates and, 23–26
thoracic, fentanyl–induced, intensive care of neonates and, 23–26
Risk factors
maternal
for abnormal vascular coiling of umbilical cord, 441–445
for perinatal septicemia due to Enterobacteriaceae, 19–22
septicemia due to multiresistant Klebsiella pneumoniae in neonatal unit and, 35–39
socioeconomic status as, for bacterial vaginosis in black or in white women, preterm prediction study and, 41–45
for symptomatic uterine rupture during trial of labor, 385–389
Rupture
of membranes
Gram-stain diagnosis of bacterial vaginosis after, 315–318
preterm premature, effect of antibiotic therapy in, on neonatal mortality and morbidity, 237–241
symptomatic uterine, risk factors for, during trial of labor, 385–389

Saliva of patients with hyperemesis gravidarum, frequent presence of Helicobacter pylori genome in, 243–247
Sandifer's syndrome in breast-fed infant, 147–150
Scintigraphy, 99MTc-Sestamibi, noninvasive assessment of myocardial perfusion with, survival after intrauterine myocardial infarction and, 309–313
Screening growth-retarded infants for TORCH infections, yield and costs of, 131–135
Sedation, fentanyl-induced muscle rigidity in intensive care of neonates and, 23–26
Sepsis
neonatal
cytokines and, 393–404
growth-restricted versus approximately grown preterm infants, neonatal outcome in, 187–192
preterm and term infants with, neutrophil chemotaxis and random migration in, 107–112
Septal hypertrophy, asymmetrical, in newborn infants of diabetic mothers, 89–94
Septicemia
due to multiresistant Klebsiella pneumoniae in neonatal unit, 35–39
perinatal, due to Enterobacteriaceae, maternal risk factors for, 19–22
Serotonin, hyperemesis gravidarum and, 209
Serum leptin concentrations during perinatal period, 325–328
Sestamibi scintigraphy, noninvasive assessment of myocardial perfusion with, survival after intrauterine myocardial infarction and, 309–313
Severe aortic thrombosis in neonates, treatment of, with low-molecular-weight heparin, 151–158
Severe preeclampsia, critical care of HELLP syndrome with corticosteroids and, 417–422
SGA infants, *see* Small-for-gestational-age infants
Shirodkar operation, modified, modifications to, 437–439
Shirodkar tape, removal of, modifications to modified Shirodkar operation and, 437–439
Sickle cell trait, maternal, and fetal hypoxia, 367–370
Single umbilical artery, association of, with increased incidence of structural and chromosomal anomalies and growth restriction, 229–232

Small-for-gestational-age (SGA) infants
antenatal detection of, influence of, on their two-year outcomes, 73–81
growth-restricted versus approximately grown preterm infants, neonatal outcome in, 187–192
hypoglycemia and, 16–17
Socioeconomic status as risk factor for bacterial vaginosis in black or in white women, preterm prediction study and, 41–45
Spirometry, weighted, surfactants and, 380
Splenomegaly in neonate, perinatal lethal form of Gaucher's disease presenting with hemosiderosis and, 201–206
Staphylococcal infections, maternal-fetal, 423–427
Static compliance and functional residual capacity, during first year in preterm infants treated with surfactant, 377–384
Steroids, hyperemesis gravidarum and, 214
Structural anomalies, association of single umbilical artery with increased incidence of, 229–232
Surfactant, 335–342
functional residual capacity and static compliance during first year in preterm infants treated with, 377–384
Surfactant protein B deficiency, hereditary, recurrent familial neonatal deaths and, 219–224
Surgical intervention, fetal, 277–283
Survival after intrauterine myocardial infarction, noninvasive assessment of myocardial perfusion with 99MTc-Sestamibi scintigraphy and, 309–313
Symptomatic patent ductus arteriosus, low-dose continuous indomethacin in early days of age in reduction of incidence of, without adverse effects, 271–275
Symptomatic uterine rupture, risk factors for, during trial of labor, 385–389

Tape, Shirodkar, removal of, modifications to modified Shirodkar operation and, 437–439
99MTc-Sestamibi scintigraphy, noninvasive assessment of myocardial perfusion with, survival after intrauterine myocardial infarction and, 309–313
Temperature
axillary, continuous measurement of core body temperature in preterm infants and, 257–264
core body, continuous measurement of, in preterm infants, 257–264
maternal, association between epidural analgesia and intrapartum fever and, 127–130
Term newborns
persistent pulmonary hypertension after maternal naproxen ingestion in, 69–71
with sepsis, neutrophil chemotaxis and random migration in, 107–112
Thermal capabilities, maturation of, in preterm infants, 47–51
Thermal control, maturation of thermal capabilities in preterm infants and, 47–51
Thermometry, transcutaneous, continuous measurement of core body temperature in preterm infants and, 257–264
Thoracic rigidity, fentanyl-induced, intensive care of neonates and, 23–26
Thrombosis, severe aortic, in neonates, treatment of, with low-molecular-weight heparin, 151–158
Thyrotoxicosis, hyperemesis gravidarum and, 208–209
Titers, TORCH, yield and costs of screening growth-retarded infants for, 131–135
TORCH infections, yield and costs of screening growth-retarded infants for, 131–135
TORCH titers, yield and costs of screening growth-retarded infants for TORCH infections and, 131–135
Total parenteral nutrition, congenital chylothorax and, 121–126
Transcutaneous thermometry, continuous measurement of core body temperature in preterm infants and, 257–264
Transient renal tubular acidosis in pregnancy, 249–252
Transplantation, liver, obstetrical and neonatal outcome in pregnancies after, 299–302
Trial of labor, risk factors for symptomatic uterine rupture during, 385–389
Triglycerides, medium chain, congenital chylothorax and, 121–126
Tubular acidosis, transient renal, in pregnancy, 249–252
Twin deliveries, outcome of, according to first twin presentation and method of delivery, 303–307
Two-year outcomes, influence of antenatal detection of small-for-gestational-age babies on, 73–81

Ultrasound versus clinical estimation of fetal weight, comparison of, 233–236
Umbilical artery, single, association of, with increased incidence of structural and chromosomal anomalies and growth restriction, 229–232
Umbilical blood gases, association of recent cocaine use with fetal acidemia or other manifestations of intrapartum fetal distress and, 63–67
Umbilical coiling index, maternal risk factors for abnormal vascular coiling of umbilical cord and, 441–445
Umbilical cord
abnormal vascular coiling of, maternal risk factors for, 441–445
serum leptin concentrations during perinatal period and, 325–328
Unfavorable cervix, correlation among amniotic fluid index, cesarean section rate, and labor length in inducted pregnancies beyond 41 weeks' gestation with, 319–324
Upper gastrointestinal dysmotility, hyperemesis gravidarum and, 209–210
Uterine contractile agents, risk factors for symptomatic uterine rupture during trial of labor, 385–389
Uterine rupture, symptomatic, risk factors for, during trial of labor, 385–389

Vacuum, instrumental delivery of fetal head at time of elective repeat cesarean and, 265–269
Vaginal delivery, neonatal hematocrit and, 163–165
Varicella, congenital, central nervous system involvement without dermatological features, 253–256
Vascular coiling, abnormal, of umbilical cord, maternal risk factors for, 441–445
Vasospasm of cerebral arteries, hyperemesis gravidarum and, 212–213
Vein of Galen, persistent pulmonary hypertension of newborn presenting as primary manifestation of intracranial arteriovenous malformation of, 405–410
Veno-venous versus veno-arterial ECMO, 347
Ventilation, high-frequency, in neonates, 1–9
Ventilatory styles, surfactants and, 335–342
Version, external cephalic, successful, labor and delivery following, 183–186
Vitamin A, antioxidant defenses of preterm infant and, 170–171

Vitamin B12 and folate bioavailability from two prenatal multivitamin/multimineral supplements, 193–199
Vitamin C, antioxidant defenses of preterm infant and, 171–172
Vitamin E, antioxidant defenses of preterm infant and, 170
Vitamins, hyperemesis gravidarum and, 213
Vomiting, pernicious, hyperemesis gravidarum and, 207–218

Warmer, radiant, continuous measurement of core body temperature in preterm infants and, 257–264
Water–soluble compounds, antioxidant defenses of preterm infant and, 171–173
Weaning from extracorporeal membrane oxygenation, 351
Weight, fetal, comparison of clinical versus ultrasound estimation of, 233–236
Weighted spirometry, surfactants and, 380
Wernicke's encephalopathy, hyperemesis gravidarum and, 212
White women, socioeconomic status as risk factor for bacterial vaginosis in, preterm prediction study and, 41–45
Women, socioeconomic status as risk factor for bacterial vaginosis in, preterm prediction study and, 41–45